The stock of Novo Nordisk A/S (NVO) is currently priced at $162.18. In the last session, the stock climbed significantly, topping out at $162.92 after opening at $162.51. The day’s lowest price was $161.47 before the stock closed at $161.78.
Novo Nordisk A/S’s market performance has been stable in recent times. The company’s stock hit a 1-year high of $172.97 on 04/21/23 and a low of $95.02 for the same time frame on 09/26/22.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
52-week price history of NVO Stock
Studying a stock’s 52-week price history, which includes both low and high prices, can help gauge its current status and potential future performance. Novo Nordisk A/S’s current trading price is -6.24% away from its 52-week high, while its distance from the 52-week low is 70.68%. The stock’s price range during the 52-week period has remained between $95.02 and $172.97. In the Healthcare sector, the company’s shares saw a trading volume of around 0.7 million for the day, which was evidently lower than the average daily volume of 1.43 million over the past three months.
Market Capitalization and Financial Performance: An In-Depth Look
Novo Nordisk A/S (NVO) has experienced a quarterly rise of 14.53% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 273.40B and boasts a workforce of 57089 employees.
A Closer Look at Analysts’ Ratings for Novo Nordisk A/S
As of right now, 15 analysts are rating Novo Nordisk A/S as a BUY, 1 of the polled analysts branded the stock as an OVERWEIGHT, 7 analysts are recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 3 analysts are rating the stock as SELL.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 151.00, with a change in price of +26.21. Similarly, Novo Nordisk A/S recorded 1,426,298 in trading volume during the last 100 days, posting a change of +19.37%.
Examining NVO’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for NVO stands at 0.32. Similarly, the long-term debt-to-equity ratio is also 0.30.
NVO Stock Stochastic Average
As of today, Novo Nordisk A/S’s raw stochastic average for the last 50 days stands at 69.67%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 22.00%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 27.21% and 48.67%, respectively.
NVO Stock Price Performance Analysis
The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. The metric has seen a significant gain of 19.83% since the start of this calendar year. Looking back over the last six months, we can see a weaker performance of 40.56%. Over the past 30 days, the price of NVO has leaped by -1.70%. And in the last five days, it has fallen by -3.78%.